Health Kick podcast: Chronic kidney disease is a worldwide health crisis, ASX-listed DXB is driving improved treatment
Health & Biotech
share
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.
In this episode Tim chats with CEO and MD of Dimerix, Nina Webster.
Dimerix (ASX:DXB) focuses on chronic kidney diseases, including diabetic kidney disease.
The company’s lead drug, DMX 200, is proposed as an adjunct therapy for patients receiving irbesartan, the current standard of care treatment for kidney disease.
In the US, Dimerix has ‘orphan indication” for the kidney scarring disease FSGS (focal segmental glomerulosclerosis) and is also furthering a treatment for chronic obstructive pulmonary disease.
On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!
